title: Human papillomavirus vaccination: where are we now?
abstract: The development of efficacious prophylactic human papillomavirus vaccines provided an opportunity for the primary prevention of related infections and diseases. Certain oncogenic human papillomaviruses that preferentially infect the genital epithelium cause cervical cancer and a substantial proportion of anal, penile, vaginal, vulvar and oropharyngeal cancers. Following extensive clinical trials demonstrating their efficacy and safety, two vaccines have been in global use for over 6 years. This review summarises the accumulated evidence regarding their high level of efficacy, safety in population usage, reductions in genital warts, infections and cervical disease following their adoption, and facilitators and barriers to achieving high vaccination coverage. The review also discusses practical issues and frequently asked questions regarding duration of effect, vaccination of women treated for cervical disease and alternate vaccination schedules, as well as the need to review cervical screening strategies in the post- vaccination environment.
authors.affiliation: National HPV Vaccination Program Register, VCS Inc, East Melbourne, Victoria, Australia.
authors.forename: Julia M L
authors.initials: JM
authors.lastname: Brotherton
mesh_terms: D003218:Condylomata Acuminata / Q000517:prevention & control / Q000821:virology; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000150:complications / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D017410:Practice Guidelines as Topic / Q000592:standards; D002577:Uterine Cervical Diseases / Q000517:prevention & control* / Q000821:virology*; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines
keywords: immunisation programme; mass vaccination; papillomavirus vaccine; uterine cervical neoplasm